Indegene Limited held its Q4 and FY26 earnings conference call, reporting its first-ever quarter with revenue exceeding ₹1,000 crores and annual revenue crossing ₹3,500 crores.
Management highlighted strong growth driven by GenAI-led solution wins, strategic acquisitions, and a deepening relationship with its top 20 global pharma clients.
The company provided an optimistic outlook for FY27, expecting Tectonic engagements and AI-driven operating models to become material growth drivers.
CFO Suhas Prabhu detailed financials, including a one-time provision for a U.S. class action lawsuit and strong cash flow generation of ₹6,508 million for the year.